» » »

Cancer Drug Responses Durham NC

new way to predict which brain cancer patients will respond to the drug Avastin has been developed by U.S. researchers.

Douglas Rivera, MD
Durham, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Timothy Alan Driscoll, MD
Box #2916 Duke University Medical Cntr,
Durham, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Oh State Univ Coll Of Med, Columbus Oh 43210
Graduation Year: 1990

Data Provided by:
Cristina Gasparetto, MD
Erwin Road,
Durham, NC
Specialties
Oncology (Cancer)
Gender
Female
Education
Medical School: Univ Di Roma-La Sapienza, Fac Di Med E Chirurgia, Roma, Italy
Graduation Year: 1986

Data Provided by:
Phillip Febbo
(919) 620-4467
Duke University Medical Ctr
Durham, NC
Specialty
Hematology / Oncology, Medical Oncology

Data Provided by:
Thomas Roberts Kinney, MD
(919) 489-9704
Box 3462,
Durham, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Duke Univ Sch Of Med, Durham Nc 27710
Graduation Year: 1970

Data Provided by:
Keith Michael Sullivan, MD
(919) 668-1011
Dumc Box 3961,
Durham, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: In Univ Sch Of Med, Indianapolis In 46202
Graduation Year: 1971

Data Provided by:
Joanne Jenkins Lager, MD
(919) 684-3401
Erwin Road,
Durham, NC
Specialties
Oncology (Cancer)
Gender
Female
Education
Medical School: Duke Univ Sch Of Med, Durham Nc 27710
Graduation Year: 1998

Data Provided by:
David Guy Kirsch
(919) 684-8111
2100 Erwin Rd
Durham, NC
Specialty
Radiation Oncology

Data Provided by:
John Chung
(919) 620-4467
2100 Erwin Rd
Durham, NC
Specialty
Hematology / Oncology

Data Provided by:
Andrew Berchuck, MD
(919) 684-3765
PO Box 3079,
Durham, NC
Specialties
Oncology (Cancer), Gynecological Oncology
Gender
Male
Education
Medical School: Case Western Reserve Univ Sch Of Med, Cleveland Oh 44106
Graduation Year: 1980

Data Provided by:
Data Provided by:

Cancer Drug Responses

Provided By:

A new way to predict which brain cancer patients will respond to the drug Avastin has been developed by U.S. researchers.

Avastin, which shrinks tumors by cutting off their blood supply, was approved this spring by the U.S. Food and Drug Administration for treatment of aggressive brain cancer. However, half of those with the cancer don't respond to the drug, which can cost up to $10,000 a month, according to a news release from the University of California, Los Angeles.

UCLA researchers examined 82 people who had surgery and radiation to treat glioblastoma, the most common and deadly form of adult brain cancer. Half of them were given infusions of Avastin every two weeks, and all had monthly MRI brain scans to monitor changes.

An analysis of the scans showed that there was greater water movement in the tumors of people who later had the best response to Avastin. By using MRI to measure the amount of water motion within the tumor, the researchers were able to predict with 70 percent accuracy which tumors would progress within six months and which would not.

Increased water movement in tumors is linked with higher levels of a growth factor called VEGF, which is secreted by a tumor to promote the growth of new blood vessels that provide the tumor with oxygen and nutrients. Avastin blocks VEGF, the researchers explained.

"When we realized that high levels of VEGF are linked to greater cell death and increased water movement, we were able to predict the patients' response to Avastin before they began treatment," lead author Dr. Whitney Pope, assistant professor of radiological sciences at UCLA's David Geffen School of Medicine, said in the news release.

"We were correct 70 percent of the time," Pope said. "Previously, identifying which patients would respond was like flipping a coin. This is a huge improvement."

The study appears in the July issue of Radiology.

"Knowing this information ahead of time will help doctors personalize therapy for each patient and decrease exposure to side effects," Pope said.

He and a co-author are consultants for Genentech, which makes Avastin, and are working with the company on several research studies.

More information

The U.S. National Cancer Institute has more about brain tumors.

SOURCE: University of California, Los Angeles, news release, July 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com